This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Bromodomain containing 4 (BRD4)	Studies in cell culture and in mice suggest inhibiting BRD4 could help treat AML. In a panel of human AML cell lines and primary AML samples, the small molecule BRD4 inhibitor JQ1 decreased proliferation compared with vehicle control. In a mouse model of AML, this inhibitor delayed disease progression and prolonged survival. Next steps include screens to identify additional chromatin-associated proteins that can be therapeutically targeted in cancer.	Patent application filed; licensed to Tensha Therapeutics Inc.	Zuber, J. <i>et al. Nature</i> ; published online Aug. 3, 2011; doi:10.1038/nature10334 Contact: Christopher R. Vakoc, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. e-mail: vakoc@cshl.edu
<i>SciBX</i> 4(31); doi:10.1038/scibx.2011.875 Published online Aug. 11, 2011				